Targeting muscle to provide healthy weight loss and metabolic fitness
Approach:
Obesity and overweight are increasingly being recognized as a health issue of epidemic proportions, impacting over 1 billion patients worldwide and associated with a growing list of comorbidities. Thanks to medical and pharmaceutical innovation, a new class of weight loss agents has emerged – the GLP-1 receptor agonists (GLP1 RA)- GLP1 Ras are believed to act by promoting satiety and helping with weight management.
At SixPeaks Bio we believe that protection of lean tissue mass will be a core component for future healthy weight management solutions. We are targeting preservation and potentially an expansion of skeletal muscle mass as a future therapeutic companion to GLP1 RAs.
Muscle at the center of obesity
Lead program targeting ActR2A/B
Potential best in class ActR2A/B lead program, experienced team with deep knowledge in ActR2A/B biology and mAb engineering
Versatile toolbox
Antibodies and conjugates platform
State of the art antibody engineering and conjugation platform capabilities, world class core team in place
